COLLPLANT BIOTECH. IS-01 (CPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has a cash flow conversion efficiency ratio of -0.483x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.94 Million ≈ $-3.43 Million USD) by net assets (€6.08 Million ≈ $7.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
COLLPLANT BIOTECH. IS-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read COLLPLANT BIOTECH. IS-01 (CPT) financial obligations for a breakdown of total debt and financial obligations.
COLLPLANT BIOTECH. IS-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anglo Asian Mining Plc
LSE:AAZ
|
0.159x |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
0.015x |
|
Gratomic Inc
V:GRAT
|
-0.003x |
|
Vectus Biosystems Ltd
AU:VBS
|
2.572x |
|
Binani Industries Limited
NSE:BINANIIND
|
0.019x |
|
Kingman Minerals Ltd
V:KGS
|
-0.113x |
|
MOVIE GAMES S.A. ZY1
F:2LH
|
0.070x |
|
Munic SA
PA:ALMUN
|
0.112x |
Annual Cash Flow Conversion Efficiency for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see COLLPLANT BIOTECH. IS-01 market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.08 Million ≈ $7.11 Million |
€-9.42 Million ≈ $-11.01 Million |
-1.549x | -47.99% |
| 2024-12-31 | €13.46 Million ≈ $15.74 Million |
€-14.09 Million ≈ $-16.48 Million |
-1.047x | -973.53% |
| 2023-12-31 | €28.34 Million ≈ $33.13 Million |
€-2.76 Million ≈ $-3.23 Million |
-0.097x | +77.02% |
| 2022-12-31 | €32.28 Million ≈ $37.74 Million |
€-13.70 Million ≈ $-16.01 Million |
-0.424x | -865.55% |
| 2021-12-31 | €45.12 Million ≈ $52.75 Million |
€2.50 Million ≈ $2.92 Million |
0.055x | -- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more